COSMOS HEALTH NEW DL-01 Cash Flow Conversion Efficiency
COSMOS HEALTH NEW DL-01 cash flow conversion efficiency. Based on the latest financial reports, COSMOS HEALTH NEW DL-01 (V67A) has a cash flow conversion efficiency ratio of -0.249x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.60 Million ≈ $-5.37 Million USD) by net assets (€18.42 Million ≈ $21.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of COSMOS HEALTH NEW DL-01 (2021–2025)
Cash flow conversion efficiency of COSMOS HEALTH NEW DL-01 from 2021 to 2025. This chart illustrates how COSMOS HEALTH NEW DL-01's cash flow conversion efficiency has evolved over time, based on yearly financial data. View V67A live share price for real-time trading data and today's change.
COSMOS HEALTH NEW DL-01 Cash Flow Conversion Ratio Explained
COSMOS HEALTH NEW DL-01 cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
COSMOS HEALTH NEW DL-01 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of COSMOS HEALTH NEW DL-01 ranked by their cash flow conversion efficiency. Also see market cap of COSMOS HEALTH NEW DL-01 for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RN2 Technologies Co. Ltd
KQ:148250
|
0.001x |
|
Big Pharma Split Corp Class A
TO:PRM
|
-0.053x |
|
Yulho Co. Ltd
KQ:072770
|
-0.042x |
|
Madhav Copper Limited
NSE:MCL
|
0.168x |
|
Equity Metals Corp
V:EQTY
|
-0.520x |
|
INCREDIBLE INDUSTRIES LIMITED
NSE:INCREDIBLE
|
0.022x |
|
INNO-GENE SA ZY -10
F:WQ3
|
0.003x |
|
Wellchange Holdings Company Limited
NASDAQ:WCT
|
0.029x |
Annual Cash Flow Conversion Efficiency for COSMOS HEALTH NEW DL-01 (2021–2025)
The table below shows the annual cash flow conversion efficiency of COSMOS HEALTH NEW DL-01 from 2021 to 2025. Review COSMOS HEALTH NEW DL-01 (V67A) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €18.42 Million ≈ $21.54 Million |
€-8.45 Million ≈ $-9.88 Million |
-0.458x | -45.76% |
| 2024-12-31 | €24.53 Million ≈ $28.68 Million |
€-7.72 Million ≈ $-9.02 Million |
-0.315x | +27.49% |
| 2023-12-31 | €36.04 Million ≈ $42.14 Million |
€-15.64 Million ≈ $-18.28 Million |
-0.434x | -15.69% |
| 2022-12-31 | €39.66 Million ≈ $46.36 Million |
€-14.87 Million ≈ $-17.39 Million |
-0.375x | +76.86% |
| 2021-12-31 | €4.38 Million ≈ $5.12 Million |
€-7.10 Million ≈ $-8.30 Million |
-1.621x | -- |
About COSMOS HEALTH NEW DL-01
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company offers prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It als… Read more